Welcome to our dedicated page for Nymox Pharm news (Ticker: NYMXF), a resource for investors and traders seeking the latest updates and insights on Nymox Pharm stock.
Nymox Pharmaceutical Corporation (NYMXF) is a clinical-stage biopharmaceutical company developing innovative therapies for age-related conditions, including its lead candidate fexapotide triflutate for prostate diseases. This page provides authorized news updates and press releases directly from the company and verified financial media.
Investors and healthcare professionals will find timely updates on clinical trial progress, regulatory milestones, and diagnostic product developments. Our curated feed includes essential announcements about:
• Phase III clinical trial results
• FDA and international regulatory filings
• Diagnostic assay innovations
• Strategic partnerships
• Financial performance reports
Bookmark this page for direct access to primary-source information about Nymox's advancements in urology treatments and Alzheimer's diagnostic tools. Check regularly for official updates impacting the company's research pipeline and market position.
Nymox has announced the dismissal of its Delaware legal action against Ascella on March 7, 2025. The company stated this decision came after reconsidering its strategy to protect shareholders' interests. CEO Paul Averback indicated this dismissal is a legal step taken after consultation with legal counsel, and mentioned that additional steps are being contemplated, which will be reported at an appropriate time.
Nymox Pharmaceutical (NYMXF) has announced the resumption of its stock trading on the OTCQB Venture Market, representing an upgrade from its previous listing tier. This new listing makes the stock eligible for proprietary broker-dealer quotations. The company's president, Paul Averback, expressed gratitude towards the OTC teams for their guidance during the transition process and thanked shareholders and investors for their patience and support. He emphasized the company's focus on advancing prostate treatments to address the market's need for safer and more effective solutions.
Nymox Pharmaceutical (OTC: NYMXF) has announced the filing of its Annual Report with the Securities and Exchange Commission (SEC) on August 29, 2024. The company, which trades on the OTC Markets, made this announcement on August 30, 2024, from Irvine, California. This timely filing of the Annual Report is a important regulatory compliance step for publicly traded companies, providing investors and regulators with essential financial and operational information about the company's performance over the past year.
Nymox Pharmaceutical (OTC: NYMXF) has announced an update on its Annual Report progress. The company began working on the report in late February after receiving previously withheld corporate documents from terminated officers and directors. This situation has led to unexpected delays in completing the report. Despite these challenges, Nymox expects the audit to be finalized soon, with the Annual Report to be issued shortly after. The company acknowledges the delay is beyond its control and is working to release the report as quickly as possible.
Nymox Pharmaceutical (OTC: NYMXF) announced that its Marketing Authorization Application (MAA) to the Danish Medicines Agency (DKMA) for Nymozarfex™ has expired and requires resubmission with a new fee. The current application does not meet the Medicines Act conditions for marketing authorization. Key issues include:
1. Developing an assay method for impurities below 0.1%
2. Providing additional evidence of double-blinding in long-term follow-up studies
3. Addressing remaining questions about data analysis
Nymox believes it has the necessary data for resubmission but cannot guarantee resolution of all issues. The company's MAA to the UK's MHRA is still in process. No significant safety concerns were reported for Nymozarfex in human clinical trials.
FAQ
What is the current stock price of Nymox Pharm (NYMXF)?
What is the market cap of Nymox Pharm (NYMXF)?
